Daily Respiratory Research Analysis
Analyzed 140 papers and selected 3 impactful papers.
Summary
A phase 3 randomized trial showed that giving immunochemotherapy for advanced NSCLC earlier in the day significantly prolonged progression-free and overall survival. Multicenter test-negative data from the US estimated that 2024–2025 COVID-19 vaccines protected against hospitalization and severe in-hospital outcomes across circulating JN.1 descendant lineages. A large self-controlled case series found sharply elevated risks of cardiorespiratory events after RSV-related hospitalization, underscoring the need for vaccination and post-discharge monitoring.
Research Themes
- Chronotherapy to optimize immunochemotherapy in lung cancer
- Real-world effectiveness of updated COVID-19 vaccines across evolving variants
- Post-viral cardiovascular and respiratory risks after RSV hospitalization
Selected Articles
1. Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial.
In a multicenter phase 3 RCT, administering anti–PD-1–based immunochemotherapy before 15:00 significantly improved PFS (11.3 vs 5.7 months; HR 0.40) and OS (28.0 vs 16.8 months; HR 0.42) in advanced NSCLC without new safety concerns. Immune-related adverse events were similar across groups.
Impact: This is a large, randomized, phase 3 chronotherapy trial showing clinically meaningful survival gains with a simple scheduling change. It could immediately influence infusion timing policies.
Clinical Implications: For advanced NSCLC receiving anti–PD-1–based chemoimmunotherapy, scheduling infusions earlier in the day may be adopted to maximize efficacy without added toxicity. Oncology services should consider operational shifts to accommodate morning administrations.
Key Findings
- Early ToD immunochemotherapy improved median PFS to 11.3 vs 5.7 months (HR 0.40; P<0.001).
- Early ToD improved median OS to 28.0 vs 16.8 months (HR 0.42; P<0.001).
- No new safety signals; immune-related adverse events were similar between groups.
Methodological Strengths
- Randomized, phase 3, multicenter design with clear ToD definition.
- Clinically relevant endpoints (PFS, OS) with adequate follow-up (median 28.7 months).
Limitations
- Open-label design could introduce performance bias.
- Driver mutation–negative population; generalizability to broader NSCLC subsets needs confirmation.
Future Directions: Validate ToD effects across different immunotherapy backbones, PD-L1 strata, and real-world settings; assess mechanisms (circadian immune dynamics) and cost–operational impacts of morning scheduling.
Retrospective studies suggest that early time-of-day (ToD) infusions of immunochemotherapy may improve efficacy. However, prospective randomized controlled trials are needed to validate it. In this randomized phase 3 LungTIME-C01 trial, 210 patients with treatment naive stage IIIC-IV nonsmall cell lung cancer (NSCLC) lacking driver mutations were randomly assigned in a 1:1 ratio to either an early or late ToD group, defined by the administration of the first four cycles of an anti-PD-1 agent before or after 15:00 h. The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS) and objective response rate (ORR). After a median follow-up of 28.7 months, the median PFS was 11.3 months (95% confidence interval (CI) = 9.2-13.4) in the early ToD group and 5.7 months (95% CI = 5.2-6.2) in the late ToD group, corresponding to a hazard ratio (HR) for earlier disease progression of 0.40 (95% CI = 0.29-0.55; P < 0.001). The median OS was 28.0 months (95% CI = not estimable (NE)-NE) in the early ToD group and 16.8 months (95% CI = 13.7-19.9) in the late ToD group, corresponding to an HR of an earlier death of 0.42 (95% CI = 0.29-0.60; P < 0.001). Treatment-related adverse events were consistent with the established safety profile, with no new safety signals observed. No significant differences in immune-related adverse events were observed between the two groups. Over the first four cycles, morning circulating CD8
2. Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19.
In 8,493 hospitalized adults across 26 US hospitals, 2024–2025 COVID-19 vaccines were 40% effective against hospitalization and 79% effective against invasive mechanical ventilation or death. Effectiveness persisted through 90–179 days and was observed across multiple JN.1 descendant lineages, with lineage-specific estimates influenced by time since vaccination.
Impact: Provides timely, lineage-aware vaccine effectiveness estimates against severe outcomes during ongoing viral evolution, informing booster timing and vaccine composition decisions.
Clinical Implications: Supports use of updated vaccines to reduce severe COVID-19 outcomes and hospitalizations, with benefits sustained up to ~6 months; underscores importance of genomic surveillance and lineage-informed VE monitoring for policy.
Key Findings
- Overall VE against hospitalization was 40% (95% CI, 27–51%).
- VE against invasive mechanical ventilation or death was 79% (95% CI, 55–92%).
- Lineage-specific VE: 49% against KP.3.1.1, 34% against XEC, and 24% against LP.8.1, with estimates influenced by longer time since vaccination for later-circulating lineages.
Methodological Strengths
- Multicenter test-negative case-control design with adjustment for key confounders.
- Integration of whole-genome sequencing for lineage-specific VE estimates and mutation-stratified analyses.
Limitations
- Lineage-specific VE estimates had reduced precision, especially for later-circulating lineages with fewer sequenced cases and longer time since vaccination.
- Residual confounding and selection biases inherent to observational designs remain possible.
Future Directions: Continue lineage-resolved VE surveillance with larger sequenced samples; evaluate durability beyond 6 months and impacts of next-generation vaccines; integrate host factors to refine risk stratification.
IMPORTANCE: As SARS-CoV-2 JN.1 lineage descendants continue to evolve, evaluating COVID-19 vaccine effectiveness (VE) against severe COVID-19 remains important to guide vaccination strategies. OBJECTIVE: To estimate the VE of the 2024-2025 COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes overall and by time since dose (7-89, 90-179, and ≥180 days), JN.1 descendant lineage (KP.3.1.1, XEC, LP.8.1), and spike protein mutations associated with immune evasion. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, test-negative, case-control study conducted by the Investigating Respiratory Viruses in the Acutely Ill Network included adult patients (aged ≥18 years) hospitalized between September 1, 2024, and April 30, 2025, at 26 hospitals in 20 US states. Case patients presented with COVID-19-like illness and positive SARS-CoV-2 nucleic acid or antigen test results; control patients had COVID-19-like illness but tested negative for SARS-CoV-2. EXPOSURE: Receipt of a 2024-2025 COVID-19 vaccine at least 7 days before illness onset. MAIN OUTCOMES AND MEASURES: Main outcomes were COVID-19-associated hospitalization and severe in-hospital outcomes (supplemental oxygen therapy, acute respiratory failure, intensive care unit admission, and invasive mechanical ventilation or death). Logistic regression was used to estimate the odds of vaccination in case and control patients, adjusting for demographics, clinical characteristics, and enrollment region. The VE was estimated as (1 - adjusted odds ratio) × 100%. RESULTS: A total of 8493 patients (median [IQR] age, 66 [54-76] years; 4338 female [51.1%]), including 1888 case patients with COVID-19 (among whom 951 [50.4%] had successful whole-genome sequencing, including 348 [36.6%] with KP.3.1.1, 218 [22.9%] with XEC, and 134 [14.1%] with LP.8.1 infections) and 6605 control patients were enrolled. Vaccine effectiveness against COVID-19-associated hospitalization was 40% (95% CI, 27%-51%), and protection was sustained through 90 to 179 days after vaccination. Vaccine effectiveness was higher against the most severe outcome of invasive mechanical ventilation or death at 79% (95% CI, 55%-92%). It was 49% (95% CI, 25%-67%) against hospitalization with KP.3.1.1, 34% (95% CI, 4%-56%) against XEC, and 24% (95% CI, -19% to 53%) against LP.8.1, with increasing median time since dose receipt among vaccinated case patients due to sequential circulation patterns (60, 89, and 141 days, respectively). The VE was similar against lineages with spike protein S31 deletion (41% [95% CI, 22%-56%]) and T22N and F59S substitutions (37% [95% CI, 9%-57%]). CONCLUSIONS AND RELEVANCE: In this multicenter, case-control analysis of VE, 2024-2025 COVID-19 vaccines may have provided protection against hospitalizations and severe in-hospital outcomes as multiple JN.1 descendant lineages circulated. Monitoring COVID-19 VE, including stratifying by SARS-CoV-2 lineage and spike protein mutations, remains important to guide COVID-19 vaccine composition and recommendations.
3. Risk of Cardiorespiratory Events Following Respiratory Syncytial Virus-Related Hospitalization.
Among 11,887 adults, the risks of MI, stroke, CHF and COPD exacerbations, and arrhythmias rose sharply after RSV-related hospitalization, peaking in the first 7–14 days (e.g., MI IRR 8.7 in days 1–7) and some remaining elevated up to 180 days. These findings align RSV with other respiratory viruses in triggering post-acute cardiopulmonary events.
Impact: Quantifies near-term and medium-term cardiopulmonary risks after RSV hospitalization in a large self-controlled design, supporting vaccination strategies and post-discharge risk management.
Clinical Implications: Adults hospitalized with RSV warrant heightened vigilance and follow-up for cardiovascular and respiratory events, especially within 2 weeks. Results support expanding RSV immunization and considering targeted post-discharge monitoring in high-risk patients.
Key Findings
- MI risk: IRR 8.7 (days 1–7), 5.2 (days 8–14), 2.6 (days 15–21) after RSV hospitalization.
- Stroke risk: IRR 7.4, 5.9, and 3.7 in the first 3 weeks; CHF exacerbation risk peaked at IRR 12.5 in days 1–7.
- COPD exacerbation (IRR 23.1 to 1.3 by week 3) and arrhythmia (IRR 16.5 to 1.6) risks declined over the first 3 weeks; some risks remained elevated up to 180 days.
Methodological Strengths
- Self-controlled case series reduces confounding by fixed patient characteristics.
- Large national claims dataset with time-varying adjustment and precise risk windows.
Limitations
- Claims-based diagnoses may misclassify exposures/outcomes; virologic confirmation tied to coding.
- Generalizability limited to hospitalized adults; unmeasured confounding by care patterns possible.
Future Directions: Assess whether RSV vaccination reduces post-acute cardiopulmonary events; develop risk stratification tools and test targeted post-discharge interventions.
IMPORTANCE: Respiratory syncytial virus (RSV) may trigger cardiorespiratory events in adults. OBJECTIVE: To assess the risk of cardiorespiratory events in the 180 days following RSV-related hospitalization compared with a control period in adults. DESIGN, SETTING, AND PARTICIPANTS: This self-controlled case series study had an observation period from January 1, 2017, through March 31, 2024. Data were obtained from the deidentified Optum Market Clarity Dataset, including RSV-related hospitalization and associated outcomes, which were identified based on diagnosis codes. Adults with 1 or more RSV-related hospitalizations and 1 or more cardiorespiratory events (myocardial infarction [MI], stroke, chronic obstructive pulmonary disease [COPD] exacerbation, congestive heart failure [CHF] exacerbation, and arrhythmia) were included. EXPOSURE: RSV-related hospitalization. MAIN OUTCOMES AND MEASURES: A conditional Poisson regression model was fitted to compare the incidence of cardiorespiratory events during the risk period (ie, ≤180 days after RSV-related hospital index date) and control periods (ie, >21 days before or >180 days after the index date). Incidence rate ratios (IRRs) and 95% CIs were estimated and adjusted for time-varying covariates. RESULTS: A total of 11 887 patients (mean [SD] age, 69.4 [15.5] years; 7303 females [61.4%]) with RSV-related hospitalization were included. An increased risk was associated with each cardiorespiratory event during the first 14 days following RSV-related hospitalization, with the highest IRR estimates observed in the initial 7 days. For MI, the IRRs were 8.7 (95% CI, 6.7-11.2) during days 1 to 7, decreasing to 5.2 (95% CI, 3.7-7.2) during days 8 to 14 and 2.6 (95% CI, 1.6-4.3) during days 15 to 21. For stroke, the IRRs were 7.4 (95% CI, 5.5-10.1), 5.9 (95% CI, 4.2-8.3), and 3.7 (95% CI, 2.3-5.9) during the first 3 weeks with a similar pattern for CHF exacerbation (12.5 [95% CI, 10.5-14.8], 4.1 [95% CI, 3.1-5.5], and 2.4 [95% CI, 1.6-3.6], respectively). For COPD exacerbation and arrhythmia, the IRRs decreased during the first 3 weeks from 23.1 (95% CI, 20.2-26.5) through day 7 to 1.3 (95% CI, 0.8-2.4) during days 15 to 21 and from 16.5 (95% CI, 14.5-18.7) to 1.6 (95% CI, 1.1-2.5), respectively. CONCLUSIONS AND RELEVANCE: This study demonstrated that RSV, similar to influenza and SARS-CoV-2, was associated with an increased risk of cardiorespiratory events 2 weeks following RSV-related hospitalization, and some conditions had significant risk elevations up to 180 days after admission. The findings reinforce the need to increase RSV immunization in adults.